High materiality8/10
BridgeBio Oncology price target lowered to $22 from $24 at Raymond James
Why it may matterVerify against the original reporting
Significant upside potential remains; valuation attractive despite downgrade.
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
BBOT received an analyst target update from Raymond James.
- Raymond James lowers BBOT target to $22; price now $8.52.
Key facts
- 01
Target: $22
- 02
Posted price: $8.52
- 03
Analyst firm: Raymond James
- 04
Analyst: Sean McCutcheon
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.